Jivi (Antihemophilic factor)

Brand Options

arrow pointer

Brand Name : Jivi

Marketing Authorization Holder : Bayer

Prescription Required

 
 
No Generic Medicine available for this medicine.

Product Details

Jivi

Jivi can be safely stored at room temperature for 6 months according to the manufacturer.

Save 75% on Jivi manufactured in Europe.

Non-english packaging is often present for European medicines- English label and English insert included. Plan in advance - allow us 7 days to ship this brand name medicine.

According to the European Medicines Agency, brand name Jivi originating from Europe is manufactured at the following site(s):Bayer AG Kaiser-Wilhelm-Allee 51368 Leverkusen Germany

Information about Jivi (Antihemophilic Factor)

Jivi is a recombinant clotting factor used in the treatment and prevention of bleeding in patients with hemophilia A. It is designed to mimic the body’s natural clotting factor VIII, which is deficient or absent in individuals with this condition.

Product Highlights

  • Treatment and prophylaxis of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency).

Key Ingredient

  • Antihemophilic factor

Key Benefits

  • Provides effective control of bleeding episodes and reduces the frequency of bleeding in patients undergoing prophylaxis.
  • Designed for extended duration of action, allowing for less frequent dosing compared to some other factor VIII products.
  • Lower incidence of inhibitor formation compared to some traditional factor VIII therapies.

Direction of Use

  • Administered by intravenous infusion after reconstitution with sterile water.
  • The dosing frequency and amount are determined by the severity of hemophilia, the site and severity of bleeding, and the patient's clinical response.
  • Healthcare providers typically provide guidance on proper administration techniques.

Safety Concerns

  • Common side effects include headache, nausea, and reactions at the injection site.
  • Serious side effects can include allergic reactions and the development of inhibitors against factor VIII, which can complicate treatment.
  • Regular monitoring is recommended for inhibitor development and overall patient response.

Avoid Jivi (Antihemophilic Factor) If

  • You have a known hypersensitivity to any component of Jivi, including recombinant factor VIII.
  • You are experiencing acute bleeding due to conditions other than hemophilia A.
  • There are specific health issues that may increase the risk of complications, such as severe liver dysfunction or specific allergies.


Image Image Image Image